Analyzing...
Loading company...
Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 1,824 full-time employees. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,552 Cr revenue.
COGS 41.8%, employees 10.7%.
“EBITDA margin for the quarter was 36.”
“we want to continue to guide to a high single digit growth you know, for next year as well.”
“expect high single digit revenue growth for FY 'twenty six, driven by strong and profitable expansion across our diversified non GPL segment and the continued ramp up of CDMO projects.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 16.9%▲ | 10.3% |
| ROCE | 21.8%▲ | 13.7% |
| Net Margin | 21.6%▲ | 7.6% |
| EBITDA Margin | 31.9%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | ₹2,552 Cr +6.9% | ₹2,387 Cr +4.5% | ₹2,283 Cr +5.6% | ₹2,161 Cr +1.8% | ₹2,123 Cr |
| Other Income | ₹60 Cr +74.7% | ₹35 Cr +187.1% | ₹12 Cr -58.4% | ₹29 Cr +96.9% | ₹15 Cr |
| Total Income | ₹2,612 Cr +7.9% | ₹2,421 Cr +5.5% | ₹2,295 Cr +4.8% | ₹2,190 Cr +2.4% | ₹2,138 Cr |
| COGS | ₹1,067 Cr -1.3% | ₹1,081 Cr +7.9% | ₹1,002 Cr -1.2% | ₹1,014 Cr -2.8% | ₹1,043 Cr |
| ₹1,835 Cr +3.8% | ₹1,767 Cr +6.2% | ₹1,664 Cr +6.6% | ₹1,562 Cr -0.7% | ₹1,573 Cr | |
| Profit Before Tax | ₹751 Cr +14.9% | ₹654 Cr +3.6% | ₹631 Cr +0.4% | ₹629 Cr +11.3% | ₹565 Cr |
| Exceptional Items | (₹26 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹187 Cr +10.9% | ₹169 Cr +5.1% | ₹160 Cr -0.8% | ₹162 Cr +10.6% | ₹146 Cr | |
| Net Profit | ₹564 Cr +16.2% | ₹486 Cr +3.1% | ₹471 Cr +0.8% | ₹467 Cr +11.5% | ₹419 Cr |
| Other Comprehensive Income | ₹1 Cr ↑ Recovery | (₹1 Cr) +77.2% | (₹5 Cr) | (₹0.29 Cr) ↓ Decline | ₹0.10 Cr |
| EPS | ₹45.99 | ₹39.63 | ₹38.43 | ₹38.11 | ₹34.17 |
| Diluted Shares | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Alivus Life Sciences Limited has informed the Exchange about Link of Recording
Alivus Life Sciences Limited has informed the Exchange regarding 'Allotment of Equity Shares under "Employee Stock Option Scheme, 2021"'.
Alivus Life Sciences Limited has informed the Exchange about Investor Presentation
Alivus Life Sciences Limited has informed the Exchange regarding a press release dated July 30, 2026, titled "Press Release of the Company for the First Quarter ended June 30, 2026.".
Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Alivus Life Sciences Limited has informed the Exchange about Schedule of meet - Earnings Call
Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Alivus Life Sciences Limited has informed the Exchange about Transcript of Earnings Call.
Alivus Life Sciences Limited has informed the Exchange about Schedule of Investors/Analyst Meeting.
Alivus Life Sciences Limited has informed the Exchange about Link of Earnings Call Recording
Alivus Life Sciences Limited has informed the Exchange about Schedule of meet - Earnings Call.
Alivus Life Sciences Limited has informed the Exchange about General Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst / Institutional Investor meeting.
Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst/Institutional Investor meetings
Alivus Life Sciences Limited has informed the Exchange about General Updates